Deferasirox tablets bulk supplier for pharma manufacturers

Deferasirox Tablets 125 mg, 250 mg, and 500 mg Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 125 mg, 250 mg, and 500 mg

Reference Brands: Exjade(Dispersible tablets);Jadenu (Film-coated Tablet)s

Deferasirox binds to excess iron in the bloodstream, forming a complex that is excreted primarily via feces. It effectively reduces iron overload in patients with chronic transfusions. Benefits include convenient once-daily oral dosing, improved patient compliance, shortened treatment duration, and prevention of organ damage caused by iron accumulation.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description: Deferasirox tablets, marketed as Exjade and Jadenu, are approved in the US by the FDA and in the EU via EMA for treating chronic iron overload in transfusion-dependent patients. Regulatory approval requires a comprehensive dossier including clinical data, manufacturing quality, safety, efficacy, and pharmacovigilance plans. In the US, FDA review involves detailed assessment, while EMA approval follows strict regional guidelines, ensuring consistent quality standards. For expert guidance on dossier preparation, regulatory pathways, and successful market access, visit PharmaTradz. Compliance with regional regulations is essential for the safe, effective, and timely approval of deferasirox tablets worldwide, supporting optimal patient management.

Deferasirox Tablets — third party manufacturing & bulk supply

Deferasirox Tablets 125 mg, 250 mg, and 500 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Deferasirox Tablets is supplied as Tablet — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Deferasirox Tablets listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Deferasirox Tablets →

Back to Listing

Frequently Asked Questions

Deferasirox tablets is listed as Tablet in 125 mg, 250 mg, and 500 mg. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Deferasirox tablets is referenced against Exjade(Dispersible tablets);Jadenu (Film-coated Tablet)s. Reference brands are shown for identification only and remain the property of their respective trademark owners.